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REVIEW
Caloric and galvanic vestibular stimulation for the treatment of Parkinson’s disease: 
rationale and prospects
David Wilkinson
School of Psychology, University of Kent, Canterbury, UK
ABSTRACT
Introduction: Deeply embedded within the inner ear, the sensory organs of the vestibular system are 
exquisitely sensitive to the orientation and movement of the head. This information constrains aspects 
of autonomic reflex control as well as higher-level processes involved in cognition and affect. The 
anatomical pathways that underline these functional interactions project to many cortical and sub- 
cortical brain areas, and the question arises as to whether they can be therapeutically harnessed.
Areas covered: The body of work reviewed here indicates that the controlled application of galvanic or 
thermal current to the vestibular end-organs can modulate activity throughout the ascending vestibular 
network and, under appropriate conditions, reduce motor and non-motor symptoms associated with 
Parkinson’s disease, a disease of growing prevalence and continued unmet clinical need.
Expert opinion: The appeal of vestibular stimulation in Parkinson’s disease is underpinned by its 
noninvasive nature, favorable safety profile, and capacity for home-based administration. Clinical 
adoption now rests on the demonstration of cost-effectiveness and on the commercial availability of 
suitable devices, many of which are only permitted for research use or lack functionality. Dose 
optimization and mechanisms-of-action studies are also needed, along with a broader awareness 
amongst physicians of its therapeutic potential.
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1. Introduction: the vestibular system as 
a therapeutic pathway
The peripheral vestibular system is cocooned within the dense 
temporal bone of the inner ear and comprises two organ 
types: the semi-circular canals and otoliths. The three semi- 
circular canals are co-located in a perpendicular arrangement 
and together detect rotational head movement across the 
three cardinal depth planes. The otoliths comprise the saccule 
and utricle and together detect linear head movement and 
gravitational pull, sensitivities that mean that the vestibular 
nerve never falls quiet. The dimensions of the vestibular 
organs seem so well optimized that over roughly seven orders 
of magnitude of mass variation in mammals, the overall size of 
the vestibular organs varies over one [1].
Mechanoreceptors within these structures sense extremely 
fine and brief movements which in turn stimulate action 
potentials that are propagated along the eighth cranial 
nerve to the vestibular brainstem nuclei. These nuclei receive 
and send projections from/to the cerebellum as well as from/ 
to neighboring nuclei involved in limbic (such as the raphe 
nuclei and locus coeruleus) and autonomic regulation [see 
2,3]. Every vestibular nucleus projects to at least several tha-
lamic nuclei (in many cases contralaterally if not bilaterally) 
which thereon link to numerous cortical destinations including 
the central parietal and occipital cortices, orbito-frontal, insular 
and temporal cortices [2]. These areas are principally involved 
in spatial, interoceptive and egocentric cognition, qualities 
that underpin the very concept of self. No brainstem fibers 
appear to project to a primary vestibular cortex or region that 
shows the domain-specific trademarks of hierarchical or topo-
graphical organization associated with other primary sensory 
areas. In non-human primates, a parieto-insular vestibular cor-
tex has however been identified [4] and in humans, analogous 
activations can be seen in the temporoparietal junction, pos-
terior insula, and posterior parietal cortex although most cells 
in this region are bi-modal or multi-modal [5–7]. This multi- 
sensory feature is one of several that distinguishes the vestib-
ular system from all other sensory systems, with multimodal 
interactions (incorporating multi-sensory convergence, trans-
formation and modulation) between visual, somatosensory 
and vestibular signals occurring in almost all vestibular 
relays [8].
The multi-sensory and diffuse nature of the vestibular pro-
jections point to a pervasive role in brain function that is 
echoed by the behavioral symptoms that accompany vestibu-
lar impairment. In a recent neuropsychological assessment of 
101 individuals with a chronic neurotological diagnosis, mostly 
vestibular migraine, over 60% passed the cutoff for clinical 
anxiety, 37% fell above the clinical cutoff for depression, 70% 
exceeded clinical cutoff for fatigue and 44% reported signifi-
cant daytime sleepiness [9]. Over half the sample reported 
visuo-spatial short-term impairment and reduced visual pro-
cessing speed. These findings accord with the outcomes from 
larger-scale epidemiological studies, including a survey of 
20,950 adults in the US which revealed that the 8% who self- 
reported vestibular vertigo were eight times more likely to 
have serious difficulty concentrating or remembering, four 
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times more likely to have limitations on daily living, and three 
times more likely to suffer from depression, anxiety or panic 
disorder [10]. In a seminal paper [11], Grimm et al. reported 
cognitive disturbances in 102 patients diagnosed with peri-
lymph fistula syndrome (a peripheral vestibular disorder) that 
included general forgetfulness, a specific deficit in auditory 
short-term memory, apraxia, and a general slowing of infor-
mation processing. Fatigue, anxiety, depression and unex-
plainable dread were also commonly observed, and 
contributed to a clinical picture described as functionally 
devastating. These clinical findings speak to a profound role 
for vestibular input in brain health and mental well-being. 
A strong advocate of this view is the renowned developmental 
psychological therapist Jean Ayres who proposed that the 
child’s relationship to gravity is even more primal than his/ 
her relationship to his/her mother [12]. According to Ayres, 
knowing which way is up and knowing that we are always 
firmly connected to the Earth is the foundation to all mean-
ingful behaviors and interpersonal relationships; an individual 
cannot follow his/her inner drive and develop emotionally or 
socially if he/she feels lost in space and is afraid to act through 
fear of spatial disorientation. One might question the founda-
tional status that Ayres attributes to the vestibular system, but 
the profound effects of vestibular dysfunction suggest that it 
shapes cognition more pervasively than any other sensory 
system. In the present context, if (as in case of disease) ves-
tibular signals can impair mental well-being then might there 
be conditions in which, by means of artificial stimulation, they 
can be clinically engineered to enhance it?
2. The approach of noninvasive vestibular 
stimulation
Several approaches have been taken to test whether efferent 
signals from the peripheral vestibular organs can be therapeu-
tically modified. Parents will be intimately familiar with the 
calming effects that can be induced by gentle, rhythmic rock-
ing although, as reported below, more compelling benefits 
can be obtained via the controlled stimulation of the 
vestibular organs using thermal or galvanic current. Thermal, 
or caloric, stimulation is traditionally achieved by irrigating the 
external ear canal with warm or cool water (or less commonly 
by air) [13]. The method of application is, as it sounds, some-
what crude, and its simplest form requires little more than an 
ice water bath and some rubber tubing. More sophisticated 
off-the-shelf devices allow flow rate, volume and temperature 
to be carefully controlled. Although surprisingly effective, the 
standard procedure relies on in-clinic administration and can 
spontaneously elicit a strong, short-lived sense of vertigo 
which may lead to nausea and sickness. Initially developed 
by Robert Bárány more than a century ago, the temperature 
changes introduced to the external ear canal find their way to 
the endolymphatic fluid of the semi-circular canals within the 
inner ear where the induced convention currents change the 
firing rate of the vestibular afferents; cold temperatures 
decrease mechanoreceptor discharge rate while warm tem-
peratures increase it [14]. By virtue of cupula deflection, 
Bárány reported that a cold stimulus produces a horizontal 
nystagmus (i.e. side-to-side involuntary eye movement) with 
the fast phase directed away from the stimulated ear while 
a warm stimulus exerts the opposite ocular-motor effect. 
Debate continues as to whether this thermo-convection 
model accounts entirely for the physiological effects observed 
during CVS [15,16] but it is widely taken to account for at least 
most of them. Although initially applied as a means of diag-
nosing vestibular deficit, the last 40 years has seen a gradual 
growth in therapeutic application which has been enhanced 
by the development of solid-state device technology that 
allows greater control over the stimulation waveforms and 
makes the devices more suitable for home-based 
administration.
The recent emergence of CVS as a neuro-therapeutic is 
paralleled by progress made with galvanic vestibular stimula-
tion (GVS). The technique involves the application of low 
amplitude (< ~2 mA), transcutaneous current to the mastoid 
processes, the bony protrusions located just behind the ears 
[17]. Several electrode configurations (i.e. bilateral monopolar, 
unilateral monopolar) are possible (especially when testing for 
unilateral vestibular impairment) although therapeutic appli-
cations most commonly use a bilateral, bipolar arrangement in 
which the anodal and cathodal electrodes are placed on 
opposite mastoids. Direct current [18], alternating current 
[19] and band-limited noise [20] waveforms are commonly 
applied but the parameter space is large and in the absence 
of dose response studies likely not yet optimized for clinical 
use. Many off-the-shelf devices are available, not least because 
they are also suitable for transcranial direct current stimula-
tion, a more common form of electrode-based, noninvasive 
brain stimulation. Most, if not all, devices are yet to be indicted 
for clinical use but are becoming increasingly suitable for self- 
administration by virtue of their simple user-interfaces and the 
capacity for researchers to pre-set stimulation programs from 
a wide range of frequency, amplitude, duty cycle and mor-
phological profiles. The tolerable side effects reported during 
low-amplitude (i.e. <2 mA) GVS, which mainly comprise mild 
itching and tingling at the electrode sites and may occasion-
ally extend to vertigo and headache, provide further incentive. 
Studies indicate that GVS activates the vestibular afferent 
Article highlights
● The diversity of pathways between vestibular brainstem centres and 
other brain areas, coupled with the strong link between a healthy 
vestibular system and mental well-being, gives good reason to test 
whether these pathways can be therapeutically modulated.
● Neuronal activity within the vestibular pathways can be simply and 
effectively modulated by means of portable stimulation devices that 
administer transcutaneous caloric or galvanic current to the periph-
eral vestibular organs of the inner ear.
● Some of the most compelling therapeutic effects have been reported 
in Parkinson’s Disease, a condition of growing prevalence and con-
tinued unmet need.
● Laboratory studies and early-phase trials indicate that vestibular 
stimulation can reduce motor symptoms, including postural instabil-
ity, rigidity and tremor, as well as non-motor symptoms that impair 
cognitive and emotional capacity.
● Larger-scale trials are now needed to replicate and further character-
ise symptom reduction in ‘real world’ care settings using affordable 
medical devices that are easy to use and programmed with stimula-
tion protocols optimised for the treatment of Parkinson’s disease.
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fibers (mostly of the irregular type) at the spike trigger zone 
although there is debate as to whether only the otoliths are 
activated or whether the semi-circular canals are too [17,21]. In 
any case, primary modulation appears to have occurred by the 
level of Scarpa’s ganglion within the internal auditory meatus 
because the effects can be recorded in these vestibular- 
cochlear neurons [22]. Anodal currents inhibit the firing rates 
of all responsive vestibular afferents regardless of their direc-
tional specificity, while cathodal currents excite them [17]. 
Similar to CVS, GVS elicits a complex whole-body response 
with a bilateral bipolar configuration inferring an unexpected 
head rotation toward the cathodal side which elicits compen-
satory postural and oculomotor responses toward the oppo-
site anodal side.
The compensatory ocular-motor, postural and perceptual 
behaviors initiated by vestibular stimulation are associated 
with diffuse hemodynamic responses across cortical, striatal, 
cerebellar and thalamic structures, some of which show deac-
tivation rather than activation during PET and fMRI [5,23–25]. 
Meta-analysis of fMRI and PET studies shows activation overlap 
across bilateral peri-sylvian regions, especially in the media 
and posterior insula, parietal operculum and retro-insula cor-
tex all of which receive converging afferents from the otoliths 
and semi-circular canals [6]. Divergent patterns of activation 
are difficult to interpret because caloric and galvanic wave-
forms draw from different parameter spaces, differentially 
activate somatosensory, vagus, visual and auditory systems, 
do not share a common metric by which the ‘intensity of 
stimulation’ can be equated, and cannot be easily calibrated 
to send the same information about head position and move-
ment. Focusing on the two techniques separately, pervasive 
neurophysiological effects are nevertheless apparent. In the 
case of time-varying CVS, transcranial Doppler sonography of 
the basilar artery shows a significant increase in cerebral blood 
flow velocity that is consistent with modulation of brainstem 
centers [26]. In the case of GVS, there are changes in EEG 
power spectra and P300 morphology [19,27–29] and in rats, 
there are reports of hippocampal cell proliferation [30] striatal 
reductions in c-FOS expression, and serine and threonine 
release [31,32].
The bottom-up, endogenous manner in which CVS and GVS 
stimulate the brain contrasts with transcranial magnetic sti-
mulation and transcranial direct current stimulation. These 
more common, transcranial techniques are inherently localiza-
tionist in how they seek to modulate brain function, cannot 
easily modulate activity in deep lying areas, and are con-
strained by needing to identify both the correct part of the 
scalp to stimulate and the optimum stimulation frequency to 
apply (although the latter requirement likely also applies to 
vestibular stimulation). By activating the same ascending path-
ways as natural head movement the GVS/CVS signal, although 
artefactual in origin, is able to be processed in the same innate 
manner [33,34]. As physiological recording studies show, this 
‘bottom-up’ mode of transmission allows the signal to reach 
many levels of the central nervous system and brings oppor-
tunity to entrain a wide variety of brain oscillations [33,34].
Given the anatomical and physiological reach of the ves-
tibular system, it is perhaps unsurprising that a growing 
number of researchers conceptualize it as a therapeutic path-
way. Initial impetus for this viewpoint came from reports of 
spontaneous, albeit temporary, recovery from the lateralized 
attentional disorder of hemi-spatial neglect during CVS irriga-
tion [35–37]. Subsequent studies have shown therapeutic ben-
efit in a number of other acquired brain disorders and 
neurological conditions (see [38]) as seemingly diverse as 
minimally conscious state [39] and episodic migraine [40]. As 
described below, perhaps the most striking reports, given the 
rigorous clinical trials methodology and the breadth and long-
evity of improvement observed, are in people with Parkinson’s 
disease.
3. Vestibular stimulation in Parkinson’s disease
Parkinson’s disease is a form of neuro-degeneration that 
causes tremor, slowness of movement, muscle rigidity and 
postural instability as well as debilitating non-motor symp-
toms including insomnia, speech and memory loss, chronic 
pain, incontinence, excessive sweating, eating and swallowing 
difficulties, depression and anxiety [41]. Although of only pas-
sing relevance here, emerging evidence suggests that the 
difficulties with posture, gait, and in making saccadic and 
smooth pursuit eye movements partly reflects an underlying 
vestibular disorder [42]. The disease is the fastest growing 
neurological condition; from 1990 to 2015 the number of 
people with Parkinson’s doubled to 6 million and is expected 
to double again by 2040 [43]. The disease is incurable 
although the motor symptoms can be partly managed phar-
macologically, especially in the early stages. The non-motor 
symptoms are much more difficult to manage, both because 
of their pharmacological complexity and because they may 
not be disclosed by patients and/or are not fully recognized or 
appreciated by clinicians [41]. Yet emerging evidence suggests 
that for many individuals the non-motor symptoms are the 
major determinant of quality of life, incurring significant 
health and social care costs [44,45].
The case for trialing vestibular stimulation as a treatment 
for Parkinson’s disease is premised on the results of human 
and animal physiological studies. Tracer studies have uncov-
ered both cortical and subcortical pathways (some only di- 
synaptic) connecting vestibular brainstem nuclei to the stria-
tum, a midbrain structure heavily implicated in Parkinson’s 
disease and comprising nuclei involved in movement planning 
(see [46]). Other studies indicate that unilateral vestibular loss 
affects the expression of striatal dopamine receptors [47] and, 
perhaps most compellingly, Samoudi et al. [48] showed in 
hemi-parkinsonian rats that noisy GVS not only improved 
locomotor activity, as measured by performance on 
a rotarod, but also enhanced GABA release in the substantia 
nigra. fMRI and PET studies in humans also show physiological 
changes within the striatum (notably in dorsal areas) during 
vestibular stimulation [5,24], although the hemodynamic 
response is evident in many other brain regions including 
the cerebellum and cerebral cortex which are not only linked 
to the motor symptoms of Parkinson’s disease but many non- 
motor symptoms too [5,49]. In one recent study, Cai et al. 
showed with fMRI that both noisy and sinusoidal GVS 
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increases functional connectivity between the pedunculopon-
tine nucleus, a structure involved in the supra-spinal control of 
locomotion, and left inferior parietal regions which are also 
involved in gait as well as visuo-spatial processing and motor 
planning [50]. Although few in number, preliminary EEG stu-
dies suggest that GVS may also normalize aspects of the 
abnormal-phase coupling seen in Parkinson’s disease [51] 
and help restore inter-hemispheric connectivity [52].
The case for clinically trialing vestibular stimulation in 
Parkinson’s disease is further strengthened by a handful of 
laboratory studies which have shown that a single session of 
GVS can temporarily reduce motor symptoms, mostly those 
associated with posture and gait (which interestingly may 
partly stem from damage to the vestibular system itself). For 
example, Kataoka et al. [53] showed a reduction in postural 
instability soon after a single session of DC GVS in 3 out of the 
5 individuals assessed, while Pal et al. [54] showed a small 
reduction in backwards-forwards and side-side sway in 5 indi-
viduals with Parkinson’s during subsensory, noise stimulation. 
Samoudi et al. [55] showed in 10 individuals that a single 
session of subsensory, noisy GVS was also associated with 
shorter postural corrections after being unexpectedly pulled 
backwards. Other studies have found improvements in finger 
tapping and on a Timed Up and Go Task (which involves 
moving from sitting to walking and then walking to sitting) 
during DC GVS [56], faster rest to active transitions during 
noisy, subsensory GVS [57] and improved visuo-motor tracking 
during receipt of low, zero-mean pink noise [58].
Prompted by the need to translate the above findings into 
clinically relevant outcomes, Wilkinson and colleagues recently 
set out to determine, by means of randomized controlled trial 
methodology, if repeated sessions of vestibular stimulation, 
self-administered at home, could both prolong and diversify 
the motor improvements observed within the laboratory. They 
chose to use CVS instead of GVS given their recent, positive 
experiences with a solid-state caloric stimulation device that 
administers thermal waveforms via aluminum earpieces 
housed within an easy-to-use headset; in other neurological 
populations the device has shown high patient compliance 
during home administration and an impressive treatment and 
safety profile [40,59]. Unlike other caloric stimulators which 
typically discharge a constant temperature, the device is able 
to deliver different temperatures overtime, in the present case 
oscillating gently from ear canal temperature to ~17℃ every 
2 mins in one ear (cold currents primarily activate contralateral 
cortex), and from ear canal temperature to ~42oc every 
1 minute in the other (warm currents primarily activate ipsi-
lateral cortex) for a total period of ~20 minutes [26]. The 
waveform assigned to each ear can be periodically switched 
to prevent any vestibular-induced hemispheric bias. The time- 
varying feature of the waveform is especially important 
because it is believed to mitigate both semi-circular canal 
adaptation and the side-effects that accompany the sudden 
temperature change induced by traditional irrigation meth-
ods. Allied study also indicates that, unlike constant tempera-
ture CVS, a time-varying temperature profile can elicit 
a distinctive entraining effect on the Gosling Pulsatility Index, 
a measure of cardio-vascular resistance [26].
In an initial proof of effect study, Wilkinson et al. [60] 
recruited a single participant, aged 70, who had been diag-
nosed with Parkinson’s disease 7 years earlier. Although in 
stable receipt of anti-parkinsonian medication, he presented 
with a wide range of motor and non-motor difficulties. The 
individual continued to receive his drug medications while 
receiving CVS twice per day, initially under sham conditions 
for 1 month and then under active stimulation for 2 months. 
By end of active treatment, clinically-meaningful improve-
ment, akin to a ~ 50% reduction in symptoms, was observed 
across nearly all outcome measures during the active com-
pared to sham phase, encompassing symptoms related not 
only to mobility but also cognition, executive function, sleep, 
mood and activities of daily living. Most remarkably, many of 
these gains were still evident at 5 months follow-up.
Buoyed by the success of this single case study, Wilkinson 
and colleagues sought to replicate the outcomes in a larger- 
scale, double-blinded study that incorporated separate active 
and control arms [61,62]. The volunteer sample had a mean 
age of ~70 years and comprised individuals with a wide symp-
tom and severity profile and who were once again in stable 
receipt of anti-parkinson’s medication. As before, active CVS 
was associated with a diverse and durable pattern of clinically- 
meaningful gain at both the end of the 2 month treatment 
period and, most strongly, at 5 weeks follow-up. Persistent, 
albeit weaker, improvement was still evident 5–6 months later. 
The minimum clinically importance difference was exceeded 
on the ‘gold standard’ scales of the MDS-UPDRS I (which 
probes non-motor aspects of daily living including sleep, 
pain, urinary and constipation problems, light headedness, 
and fatigue,) MDS-UPDRS II (which probes motor aspects of 
daily living including speech, salivation, chewing, swallowing, 
eating dressing, hygiene, hobbies, tremor, walking, balance, 
and freezing) and MDS-UPDRS III (which is a motor exam that 
includes assessments of speech, facial expression, rigidity, 
upper and lower limb movement, gait, posture and tremor). 
Allied non-motor improvements were seen in 14 of the 16 
active participants across multiple sub-domains of the Non- 
Motor Symptom Scale (which capture symptoms related to 
sleep/fatigue, mood, hallucinations, memory, gastro- 
intestinal, urinary and sexual function), Montreal Cognitive 
Assessment (which is especially sensitive to short-term mem-
ory, attentional/executive and visuo-spatial problems), and the 
Hospital Anxiety and Depression scale which is sensitive to 
emotional well-being. Further evidence of a more general 
enhancement in quality of life and functional independence 
was apparent in the PDQ-39 (which interrogates the ability to 
perform activities of daily living such as getting around in 
public, avoiding certain situations and interacting with people) 
and Modified Schwab and England scale (which measures how 
independently daily chores can be completed).
These striking improvements were obtained with good 
treatment concealment (as indicated by post-study question-
naire) which was achieved by informing participants that they 
may or may not receive stimulation throughout the 2 month 
treatment period and that any unusual temperatures felt in 
the ears were not indicative of ‘active’ treatment but rather 
signaled normal device operation that people sometimes 
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reported and which did not indicate whether it was in treat-
ment or sham mode.
Equally as important, the striking improvements were not 
associated with any serious adverse events related to device 
use. Thirty-four adverse events were reported in the 46 rando-
mized subjects; 24 in the active group and 10 in the placebo 
group. Three adverse events were classified as ‘serious’, but 
none was deemed by independent clinical adjudication to be 
related to device use. Four adverse events (i.e. ear discomfort, 
dizziness/motion sickness and migraine) were considered to 
be ‘possibly’ related to device use; however, none was con-
sidered to be severe, and all resolved after the cessation of 
device use. All other adverse events were minor and were 
most likely attributable to Parkinson’s disease rather than to 
study involvement. An end-of-study device questionnaire 
revealed that the majority of participants found the device 
‘easy to use at home’ and found the actual time receiving 
stimulation as ‘enjoyable’ or ‘acceptable’.
4. Conclusion
Taken together, the experimental evidence base provides 
good, albeit preliminary, evidence that vestibular stimulation 
can provide a valuable adjuvant therapy for individuals with 
Parkinson’s disease. The handful of small laboratory studies 
conducted have shown compelling improvements in specific 
motor functions, mostly focused on posture and gait, during 
GVS. There is however need to link these observations to 
broader symptomatic improvement and quality of life mea-
sures (both motor and non-motor) and to administer long-
itudinal stimulation within more formal trials protocols to 
better leverage and assess carry over. Progress made with 
CVS contrasts to that for GVS in that far fewer mechanistic 
and laboratory studies have been conducted but a double- 
blinded, randomized controlled trial has been completed. The 
high level of efficacy shown in this trial now needs to be 
replicated in a larger sample that is drawn from a wider 
geographical region and with treatment administered through 
established ‘real world’ care pathways by healthcare staff 
rather than via a university research team. The inclusion of 
cost effectiveness measures will help determine the value of 
integrating the procedure into current, routine clinical 
practice.
5. Expert opinion
Although early stage, no other Parkinson’s therapy has yet 
demonstrated the same durable and diverse pattern of gain 
seen with vestibular stimulation. In fact very few neurological 
medicines continue to work so effectively once withdrawn, 
not least those of a non-pharmacological nature. The opti-
mism prompted by the laboratory and clinical research so far 
conducted is therefore understandable. As discussed below 
and in addition to those mentioned directly above, many 
challenges and questions must nevertheless be addressed 
before the intervention can be considered for routine care.
From a device perspective, it is still unclear how much it 
matters if the vestibular periphery is stimulated via galvanic or 
thermal currents. It also unclear by how much it matters if the 
stimulus waveform has an unchanging morphology, is sinu-
soidal or noisy, and by how much stimulus amplitude and 
frequency regulate effect. Studies show that these different 
stimulation protocols have both overlapping and separable 
effects on neural response (both haemodynamically and elec-
tro-physiologically), but their clinical relevance has yet to be 
demonstrated. Coupled with uncertainty about how long each 
stimulation session should last, how many sessions should be 
given and how long to wait between sessions, the need for 
dose optimization across an unforgivingly wide parameter 
space is clear. To some degree these methodological uncer-
tainties stem from the good safety profile (which although 
features short-lived, minor adverse reactions does not seem 
to carry a significant risk of serious adverse reaction), and 
noninvasive nature of vestibular stimulation which has 
enabled human efficacy studies to progress swiftly without 
the prior dosing and mechanism-of-action studies that typi-
cally precede drug trials. One challenge for dose optimization 
study will be to identify reliable biomarkers of clinical effect 
that can be swiftly and easily acquired; while vestibular stimu-
lation elicits reliable autonomic responses [13,17] it is 
unknown whether these accurately predict symptomatic 
reductions in Parkinson’s disease. The means by which vestib-
ular stimulation improves neurological function is varied, likely 
affecting a range of domain-global processes involved in cer-
ebrovascular regulation, central inflammation, and electrical 
oscillatory rhythm, as well as more domain-specific processes 
associated with self-motion and egocentric processing. In 
terms of identifying and understanding the underlying drivers 
of effect, this rich diversity of effect may prove both a blessing 
and a curse.
Despite the enthusiasm of people with Parkinson’s to make 
use of vestibular stimulation devices, further demonstrations 
of device effectiveness are needed before regulators will grant 
clinical adoption, clinical commissioners will pay for devices 
and doctors will prescribe them. The pace of downstream 
development will continue to rely on the mutual collaboration 
of academics (perhaps most notably neuroscientists and bio- 
engineers), clinicians, industry and of course, lay advocates. 
These ‘translational’ collaborations are not only needed to 
further demonstrate the safety and efficacy of vestibular sti-
mulation but also to develop the next generation of devices 
which would benefit from being more portable, cheaper and, 
in the fullness of time, incorporate telemetry to enable physi-
cians to remotely monitor treatment compliance and response 
and thereon download repeat or revised prescriptions from 
clinic to home. Alongside these technical developments, it will 
be important to assess vestibular stimulation within a multi- 
interventional context to establish the degree to which it 
reduces reliance on other Parkinson’s medications and/or 
magnifies their effects. As highlighted by Lee et al. in an allied 
review [63], impact will also likely be constrained by a host of 
clinical and demographic factors including disease sub-type, 
co-morbidity, age, and peripheral vestibular response.
At this stage it is difficult to recommend one form of 
vestibular stimulation over the other. Unlike CVS, GVS is con-
tra-indicated in people with electronic implants or metal in 
their head (although both techniques tend to be with-held in 
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the presence of particular ear pathology) and presently relies 
on fastening electrodes to the mastoid processes which is 
a challenge for self-administration, portability and maintaining 
a low electrical impedance. It also tends to activate only the 
irregular afferents which make up just one-third (approxi-
mately) of all primary afferents [17]. Compared to CVS, GVS 
has a smaller clinical evidence base, although much of the CVS 
literature lies within the field of acquired brain injury and 
neuropsychiatric disorder than within the field of neuro- 
degeneration considered here. On the other hand, GVS is 
easier to blind (by virtue of being sub-sensory and therefore 
imperceptible), simpler to miniaturize, and can accommodate 
a much wider range of stimulus waveforms, some of which are 
more clearly linked with neural restoration. Direct comparisons 
are also difficult because neither approach is yet optimized for 
efficacy, usability or cost of manufacture and supply, 
a frustration that is not helped by very few research groups 
actively investigating both techniques.
In closing, it would be remiss to allow the challenges that 
lie ahead to overshadow the therapeutic promise brought by 
vestibular stimulation. The equipment needed to deliver sti-
mulation can, in rudimentary form, be found in most domestic 
households and applied with relatively little expertise. Yet 
surely few would link the bewildering sensations brought 
about by lending thermal or galvanic currents to the ears 
with their profound clinical potential. The technological inno-
vations reviewed above bring an ease, safety and potency that 
make this potential realizable within the next few years. A key 
next step is to demonstrate cost effectiveness, a process that 
with funding should take no more than 5 years. In the longer- 
term, the intriguing question arises as to whether vestibular 
stimulation, be this CVS and/or GVS, can replace as opposed to 
merely supplement existing drug treatments for features of 
Parkinson’s disease.
Funding
This paper was not funded.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any 
organization or entity with a financial interest in or financial conflict with 
the subject matter or materials discussed in the manuscript. This includes 
employment, consultancies, honoraria, stock ownership or options, expert 
testimony, grants or patents received or pending, or royalties.
Reviewer disclosures





Papers of special note have been highlighted as either of interest (•) or of 
considerable interest (••) to readers.
1. Squires TM. Optimizing the vertebrate vestibular semi-circular 
canal: could we balance nay better? Phys Rev Lett. 2004;5 
(93):198106.
2. Lopez C, Blanke O. The thalamocortical vestibular system in ani-
mals and humans. Brain Res Rev. 2011;67:119–146.•• This report 
provides a comprehensive insight into the rich efferent con-
nectivity of the vestibular brainstem nuclei.
3. Balaban CD, Jacob RG, Furman JM. Neurologic bases for comorbid-
ity of balance disorders, anxiety disorders and migraine: neurother-
apeutic implications. Expert Rev Neurother. 2011;11(3):379–394.
4. Guldin WO, Grüsser O-J. Is there a vestibular cortex? Trends 
Neurosci. 1998;21:254–259.
5. Bense S, Stephan T, Yousry A, et al. Multisensory cortical signal 
increases and decreases during vestibular galvanic stimulation 
(fMRI). J Neurophysiol. 2001;85:886–899.
6. Lopez C, Blanke O, Mast FW. The human vestibular cortex revealed 
by coordinate-based activation likelihood estimation meta-analysis. 
Neuroscience. 2012;212:159–179.
7. zu Eulenburg P, Caspers S, Roski C, et al. Meta-analytical definition 
and functional connectivity of the human vestibular cortex. 
Neuroimage. 2012;60(1):162–169.
8. Angelaki DE, Cullen KE. Vestibular system: the many facets of a 
multi-modal sense. Annu Rev Neurosci. 2008;31:125–150.
9. Smith L, Wilkinson D, Bodani M, et al. Short-term memory impair-
ment in vestibular patients can arise independently of psychiatric 
impairment, fatigue and sleeplessness. J Neuropsychol. 2019;13 
(3):417–431.
10. Bigelow RT, Semenov YR, Du Lac S, et al. Vestibular vertigo and 
comorbid cognitive and psychiatric impairment: the 2008 national 
health interview survey. J Neurol Neurosurg Psychiatry. 2016;87 
(4):367–372.
11. Grimm RJ, Hemenway WG, Lebray R, et al. The perilymph fistula 
syndrome defined in mild head trauma. Acta Oto-Laryngol Suppl. 
1989;108(464):1–40.
12. Ayres AJ. Sensory integration and the child: understanding hidden 
sensory challenges. Los Angeles (CA): Western Psychological 
Services; 2005.
13. Shepard NT, Jacobson GP. The caloric irrigation test. In: Furman JM, 
Lempert T, editors. Handbook of clinical neurology. Neuro-otology; 
Amsterdam: Elsevier. 2016. p. 119–131.
14. Robert Bárány — Nobel Lecture. Some new methods for functional 
testing of the vestibular apparatus and the cerebellum. Nobelprize. 
org. Nobel Media AB; 2014. Available from: Nobelprize.org.
15. Bell A. What Bárány’s caloric test might have overlooked: the 
primary factor may be the middle ear muscles. J Heart Sci. 2019;9 
(4):9–22.
16. Longridge NS, Mallinson AI, Pothier DD. Development and under-
standing of caloric responses; an overview of the first hundred 
years. J Otolaryngol ENT Res. 2015;3(2):00056.
17. Fitzpatrick RC, Day BL. Probing the human vestibular system with 
galvanic stimulation. J Appl Physiol. 2004;96(6):2301–2316.•• This 
report provides a detailed and very readable review of how 
galvanic vestibular stimulation activates the peripheral vestib-
ular system.
18. Wilkinson D, Ko P, Kilduff P, et al. Improvement of a face perception 
deficit via subsensory galvanic vestibular stimulation. 
J Int Neuropsychol Soc. 2005;11(7):925–929.
19. Schmidt-Kassow M, Wilkinson D, Denby E, et al. Synchronised 
vestibular signals increase the P300 event-related potential elicited 
by auditory oddballs. Brain Res. 2016;1648:224–231.
20. Wilkinson D, Zubko O, Sakel M, et al. Galvanic vestibular stimula-
tion in hemi-spatial neglect. Front Integr Neurosci. 2014;8:1–13.
21. Curthoys IS, MacDougall HG. What galvanic vestibular stimulation 
actually activates. Front Neurol. 2012;3:117.
22. Courjon JH, Precht W, Sirkin DW. Vestibular nerve and nuclei unit 
responses and eye movement responses to repetitive galvanic 
stimulation of the labyrinth in the rat. Exp Brain Res. 1987;66:41–48.
23. Vitte E, Derosier C, Caritu Y, et al. Activation of the hippocampal 
formation by vestibular stimulation: a functional magnetic reso-
nance imaging study. Exp Brain Res. 1996;112(3):523–526.
6 D. WILKINSON
24. Bottini G, Karnath HO, Vallar G, et al. Cerebral representations for 
egocentric space: functional-anatomical evidence from caloric ves-
tibular stimulation and neck vibration. Brain. 2001;124 
(6):1182–1196.
25. Stephan T, Deutschländer A, Nolte A, et al. Functional MRI of 
galvanic vestibular stimulation with alternating currents at differ-
ent frequencies. Neuroimage. 2005;26(3):721–732.
26. Black RD, Rogers LL, Ade KK, et al. Non-invasive neuromodulation 
using time-varying caloric vestibular stimulation. IEEE J Transl Eng 
Health Med. 2016;4:2000310.•• This report illuminates the poten-
tial of solid-state technology to unlock the true therapeutic 
potential of caloric vestibular stimulation.
27. Wilkinson D, Ferguson H, Worley A. Galvanic vestibular stimulation 
modulates the electrophysiological response during face 
processing. Vis Neurosci. 2012;29(4–5):255–262.
28. Kim DJ, Yogendrakumar V, Chiang J, et al. Noisy galvanic vestibular 
stimulation modulates the amplitude of EEG synchrony patterns. 
PLoS One. 2013;8(7):e69055.
29. Lee JW, Lee G-E, An J-H, et al. Effects of galvanic vestibular stimula-
tion on visual memory recall and EEG. J Phys Ther Sci. 2014;26 
(9):1333–1336.
30. Zheng Y, Geddes L, Sato G, et al. Galvanic vestibular stimulation 
impairs cell proliferation and neurogenesis in the rat hippocampus 
but not spatial memory. Hippocampus. 2014;24(5):541–552.
31. Stiles L, Reynolds JN, Napper R, et al. Single neuron activity and c- 
Fos expression in the rat striatum following electrical stimulation of 
the peripheral vestibular system. Physiol Rep. 2018;6(13):e13791.
32. Stiles L, Zheng Y, Smith PF. The effects of electrical stimulation of 
the peripheral vestibular system on neurochemical release in the 
rat striatum. PLoS One. 2018;13(10):e0205869.
33. Black RD, Rogers LL. Sensory neuromodulation. Front Syst Neurosci. 
2020;14:12.
34. Lakatos P, Gross J, Thut G. A new unifying account of the roles of 
neuronal entrainment. Curr Biol. 2019;29(18):R890–905.
35. Rubens AB. Caloric stimulation and unilateral visual neglect. 
Neurology. 1985;35(7):1019–1024.
36. Geminiani G, Bottini G. Mental representation and temporal recov-
ery from unilateral neglect after vestibular stimulation. J Neurol 
Neurosurg Psychiatry. 1992;55(4):332–333.
37. Cappa S, Sterzi R, Vallar G, et al. Remission of hemineglect and 
anosognosia during vestibular stimulation. Neuropsychologia. 
1987;25(5):775–782.
38. Smith PF, Zheng Y. From ear to uncertainty: vestibular contribu-
tions to cognitive function. Front Integr Neurosci. 2013;7:84.
39. Vanzan S, Wilkinson D, Ferguson H, et al. Behavioural improvement 
in a minimally conscious state after caloric vestibular stimulation: 
evidence from two single case studies. Clin Rehabil. 2017;31 
(4):500–507.
40. Wilkinson D, Ade KK, Rogers LL, et al. Preventing episodic migraine 
with caloric vestibular stimulation: a randomized controlled trial. 
Headache. 2017 Jul;57(7):1065–1087.
41. Armstrong MJ, Okun M. Diagnosis and treatment of Parkinson’s 
disease: a review. JAMA. 2020;323(6):548–560.
42. Smith P. Vestibular functions and Parkinson’s disease. Front Neurol. 
2018;9:1085.
43. Dorsey ER, Sherer T, Okun M, et al. The emerging evidence of the 
Parkinson’s pandemic. J Parkinsons Dis. 2018;8(Suppl 1):S3–8.
44. Titova N, Chaudhuri R. Nonmotor Parkinson’s and future directions. 
Int Rev Neurobiol. 2017;134:1493–1505.
45. Duncan GW, Khoo TK, Yarnell AJ, et al. Health-related quality of life 
in early Parkinson’s disease: the impact of non-motor symptoms. 
Mov Disord. 2014;29(2):195–202.
46. Stiles L, Smith PF. The vestibular-basal ganglia connection: balan-
cing motor control. Brain Res. 2015;1597:180–188.
47. Giardino L, Zanni M, Pignataro O. DA1 and DA2 receptor regulation 
in the striatum of young and old rats after peripheral vestibular 
lesion. Brain Res. 1996;736:111–117.
48. Samoudi G, Nissbrandt H, Dutia MB, et al. Noisy galvanic vestibular 
stimulation promotes GABA release in the substantia nigra and 
improves locomotion in hemiparkinsonian rats. PLos One. 2012;7 
(1):e29308.
49. Lobel E, Kleine JF, Bihan DL, et al. Functional MRI of galvanic 
vestibular stimulation. J Neurophysiol. 1998;80(5):2699–2709.
50. Cai J, Lee S, Ba F, et al. Galvanic vestibular stimulation (GVS) 
augments deficient pedunculopontine nucleus (PPN) connectivity 
in mild parkinson’s disease: fMRI effects of different stimuli. Front 
Neurosci. 2018;12:101.
51. Lee S, Liu A, Wang ZJ, et al. Abnormal phase coupling in 
Parkinson’s disease and normalization effects of subthreshold ves-
tibular stimulation. Front Hum Neurosci. 2019;13:118.
52. Lee S, Kim D, McKeown MJ. Galvanic Vestibular Stimulation (GVS) 
effects on impaired interhemispheric connectivity in Parkinson’s 
Disease. Annu Int Conf IEEE Eng Med Biol Soc. 2017;2109–2113. 
DOI:10.1109/EMBC.2017.8037270
53. Kataoko H, Okada Y, Kiriyama T, et al. Can postural instability 
respond to galvanic vestibular stimulation in patients with 
Parkinson’s disease? J Mov Disord. 2016;9(1):40–43.
54. Pal S, Rosengren S, Colebatch J. Stochastic galvanic vestibular 
stimulation produces a small reduction in sway in Parkinson’s 
disease. J Vest Res. 2009;19:137–142.
55. Samoudi G, Jivegård M, Mulavera A, et al. Effects of stochastic 
vestibular galvanic stimulation and LDOPA on balance and motor 
symptoms in patients with Parkinson’s disease. Brain Stimul. 2015;8 
(3):474–480.
56. Khoshnam M, Häner D, Kuatsjah E, et al. Effects of galvanic vestib-
ular stimulation on upper and lower extremities motor symptoms 
in Parkinson’s disease. Front Neurosci. 2018;12:633.
57. Yamamoto Y, Struzik ZR, Soma R, et al. Noisy vestibular stimulation 
improves autonomic and motor responsiveness in central neuro-
degenerative disorders. Ann Neurol. 2005;56(2):175–181.•• This 
study provides one of the earliest forms of evidence that 
GVS may help relieve symptoms of Parkinson’s disease.
58. Lee S, Kim D, Svenkeson D, et al. Multifaceted effects of noisy 
galvanic vestibular stimulation on manual tracking behavior in 
Parkinson’s disease. Front Neurosci. 2018;12:633.
59. Wilkinson D, Morris R, Milberg W, et al. Caloric vestibular stimula-
tion in aphasic syndrome. Front Integr Neurosci. 2013;7:1–9.
60. Wilkinson D, Podlewska A, Sakel M. A durable gain in motor and 
non-motor symptoms of Parkinson’s Disease following repeated 
caloric vestibular stimulation: a single-case study. 
NeuroRehabilitation. 2016;38(2):179–182.
61. Wilkinson D, Podlewska A, Banducci S, et al. Caloric vestibular 
stimulation for the management of motor and non-motor symp-
toms in Parkinson’s disease. Parkinsonism Relat Disord. 
2019;65:261–266.•• This is the first randomised controlled trial 
to show that CVS can induce durable reductions in both motor 
and non-motor symptoms of Parkinson’s disease.
62. Wilkinson D, Podlewska A, Banducci S, et al. Caloric vestibular 
stimulation for the management of motor and non-motor symp-
toms in parkinson’s disease: intention-to-treat data. Data Brief. 
2019;25:104228.
63. Lee S, Liu A, McKeown J. Current perspectives on galvanic vestib-
ular stimulation in the treatment of Parkinson’s disease. Expert Rev 
Neurother. 2021;21(4):405–418.
EXPERT REVIEW OF MEDICAL DEVICES 7
